非小细胞肺癌组织LncRNA RP11-164P12.4表达及其临床意义

发布时间：2018-04-05 23:09

本文选题：LncRNA　切入点：RP-P.　出处：《中华肿瘤防治杂志》2017年16期

【摘要】：目的近年来研究发现,LncRNA的异常表达与肿瘤的发生、发展、浸润、转移、复发及耐药等相关,但其具体机制尚未完全阐明。本研究探讨LncRNA RP11-164P12.4在非小细胞肺癌(non-small cell lung cancer,NSCLC)组织标本中的表达及临床意义。方法收集2011-01-01-2015-12-30四川省人民医院就诊临床资料完整的125例NSCLC组织、90例癌旁组织(距癌组织2cm)及35例正常肺组织标本,通过QRT-PCR法检测LncRNA RP11-164P12.4的表达,分析其表达与临床预后的关系。结果 NSCLC组织LncRNA RP11-164P12.4的表达量为6.850±1.370,明显高于癌旁组织(1.225±0.750)和正常肺组织(1.092±0.69),差异有统计学意义,F=95.19,P0.001。LncRNA RP11-164P12.4的表达与患者的年龄、性别、吸烟史、肿瘤大小、淋巴结转移及肿瘤分化无关,差异无统计学意义,均P0.05;与疾病分期、远处转移、病理类型及生存状态明显相关,差异有统计学意义,均P0.05。LncRNA RP11-164P12.4高表达水平与NSCLC中的腺癌类型相关,P0.05;LncRNA RP11-164P12.4高表达组中腺癌的表达水平明显高于鳞癌及其他,P0.001;LncRNA RP11-164P12.4低表达组患者总生存时间(overall survival,OS)为(44.89±3.64)个月,较高表达组(21.83±3.74)个月明显延长,差异有统计学意义,χ2=49.210,P0.001。LncRNA RP11-164P12.4高表达组患者无进展生存时间(progression-free-survival,PFS)为(13.55±2.84)个月,较低表达组(24.00±2.75)个月缩短,差异有统计学意义,χ~2=50.18,P0.001;Cox多因素回归模型分析提示,LncRNA RP11-164P12.4的表达、淋巴转移远处转移和临床分期是NSCLC独立的预后因素,P0.05。结论 LncRNA RP11-164P12.4参与调节NSCLC的发生发展,可作为潜在的NSCLC诊断和预后评估的分子标志物。
[Abstract]:Objective in recent years, it has been found that the abnormal expression of LncRNA is related to the occurrence, development, invasion, metastasis, recurrence and drug resistance of the tumor, but its specific mechanism has not been fully elucidated.The purpose of this study was to investigate the expression and clinical significance of LncRNA RP11-164P12.4 in non-small cell lung cancer tissues.Methods from January 2011 to January 2015-30 in Sichuan Provincial people's Hospital, 90 cases of adjacent NSCLC tissues (2cm from carcinoma) and 35 cases of normal lung tissues were collected. The expression of LncRNA RP11-164P12.4 was detected by QRT-PCR method, and the relationship between the expression of LncRNA RP11-164P12.4 and clinical prognosis was analyzed.Results the expression of LncRNA RP11-164P12.4 in NSCLC was 6.850 卤1.370, which was significantly higher than that in paracancerous tissues (1.225 卤0.750) and normal lung tissues (1.092 卤0.69). There was no significant difference between the expression of LncRNA RP11-164P12.4 RP11-164P12.4 and age, sex, smoking history, tumor size, lymph node metastasis and tumor differentiation.The difference was not statistically significant (P 0.05), and was significantly correlated with disease staging, distant metastasis, pathological type and survival status.Distant metastasis and clinical stage of lymphatic metastasis were independent prognostic factors of NSCLC (P 0.05).Conclusion LncRNA RP11-164P12.4 is involved in the pathogenesis and development of NSCLC and can be used as a molecular marker for the diagnosis and prognosis of NSCLC.
【作者单位】：四川省医学科学院·四川省人民医院肿瘤中心;
【分类号】：R734.2

【相似文献】